WaveGuide Corporation Launches World’s First Portable NMR Device

WaveGuide Corporation today launched its new WaveGuide Formµla™, the world’s only battery-powered, compact scientific instrument that performs rapid screening and diagnostics of solid and liquid substances spanning an array of markets and applications.

The WaveGuide Formla™ micro NMR delivers performance as good or better than larger, more costly benchtop NMRs, in a portable, easy-to-use device making it ideal for applications requiring in-situ decision making, including pharmaceutical, petrochemical, food quality, food safety, and consumer product authentication applications. The WaveGuide Formla™ provides quantitative analysis for a wide range of real-world scenarios—from detecting impurities in lubricants indicative of engine and component wear to authenticating biological therapies and vaccines to rapidly screening patients for specific disease states.

The WaveGuide Formla™ represents a significant departure from large, expensive, benchtop NMR solutions. In addition to trained operators, benchtop NMR systems can require up to 24 hours for the device and sample to temperature stabilize. The WaveGuide Formla™ requires minimal user training and little to no sample preparation. After a quick internal calibration, the instrument is ready to use within seconds.

The WaveGuide Formla™ will be launched at Pittcon 2020 booth #4911 in Chicago Illinois, March 2-5, 2020. A technical presentation, “Portable Forensic Analysis of Biological Agents and Consumer Products,” will be delivered by WaveGuide’s Head of Biology, Massimiliano La Colla Ph.D., at the conference on March 4.

“Until now, the size, cost and complexity of commercially available NMR platforms has limited their use to low volume and niche applications with high fixed costs. From WaveGuide’s founding in 2015, we have worked diligently to change this paradigm, partnering with Harvard University’s Department of Physics to pioneer a new class of micro NMR analyzer technology,” said Nelson K. Stacks, CEO and President of WaveGuide Corporation. “The WaveGuide Formla™ is truly a revolutionary development, opening the door to a range of in-situ applications in healthcare, consumer products, and industrial products that were previously impractical or impossible with the existing NMR technology.”

The WaveGuide Formla™ micro NMR is based on patented technology that enables small, low-cost, inhomogeneous magnets to produce a handheld chemical analyzer based on NMR, amplifying the NMR signal-to-noise by a factor of 10,000. WaveGuide has applied for six additional patents, bolstering the core technology.

More on the features and benefits can be found here.

Hot this week

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.